Multiple Sclerosis: Epidemiology, Genetics, Symptoms, and Unmet Needs
Biomarkers for Multiple Sclerosis
In Vivo Models for Drug Discovery in Multiple Sclerosis
Protein Kinase Inhibitors for the Treatment of Multiple Sclerosis
Emerging Drugs and Targets for Remyelination in Multiple Sclerosis
Regulation of Oligodendrocyte Differentiation: New Targets for Drug Discovery in Remyelination
Cannabinoids as a Therapeutic Approach in Multiple Sclerosis
Sigma Receptors as New Target for Multiple Sclerosis
Non-coding RNA and Multiple Sclerosis: New Targets for Drug Discovery
About this book
Multiple sclerosis (MS) is a complex disease with a presumed autoimmune aetiology and few current effective treatments. Disease modifying therapies focus on the altering the natural course of relapsing and remitting MS, targeting the inflammatory response. Other targets involve tacking the cause of the disease – demyelination of axons through remyelination therapies. Due to several recent breakthroughs in the understanding of the pathophysiology of MS new targets for remyelination and immunomodulation are rapidly emerging. This book provides a comprehensive overview of drug discovery and development for the molecular basis of the disease, from new targets to drugs currently in clinical development, cellular and animal disease models to biomarkers for diagnosis and assessment in clinical trials.
Emerging Drugs and Targets for Multiple Sclerosis
is an ideal reference for any student or researcher interested in drug development for neurodegenerative diseases, autoimmune diseases and MS in particular.